These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19139202)

  • 1. Interferon beta for rheumatoid arthritis: new clothes for an old kid on the block.
    Vervoordeldonk MJ; Aalbers CJ; Tak PP
    Ann Rheum Dis; 2009 Feb; 68(2):157-8. PubMed ID: 19139202
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine kinases as targets in rheumatoid arthritis.
    Tristano AG
    Int Immunopharmacol; 2009 Jan; 9(1):1-9. PubMed ID: 18848912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis?
    Bevaart L; Vervoordeldonk MJ; Tak PP
    Arthritis Rheum; 2010 Aug; 62(8):2192-205. PubMed ID: 20506322
    [No Abstract]   [Full Text] [Related]  

  • 4. [T-614 for therapy of rheumatoid arthritis].
    Hara M
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():503-7. PubMed ID: 15799407
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for rheumatoid arthritis.
    Treat Guidel Med Lett; 2009 May; 7(81):37-46; quiz 47-8. PubMed ID: 19390497
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
    Blank N; Max R; Schiller M; Briem S; Lorenz HM
    Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
    [No Abstract]   [Full Text] [Related]  

  • 7. Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis.
    Dyckman AJ; Langevine CM; Quesnelle C; Kempson J; Guo J; Gill P; Spergel SH; Watterson SH; Li T; Nirschl DS; Gillooly KM; Pattoli MA; McIntyre KW; Chen L; McKinnon M; Dodd JH; Barrish JC; Burke JR; Pitts WJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):383-6. PubMed ID: 21087862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta.
    Corr M; Boyle DL; Ronacher L; Flores N; Firestein GS
    Ann Rheum Dis; 2009 Feb; 68(2):257-63. PubMed ID: 18653628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment and management of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.
    Naumann L; Huscher D; Detert J; Spengler M; Burmester GR; Buttgereit F
    Ann Rheum Dis; 2009 Dec; 68(12):1934-6. PubMed ID: 19910303
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibiting inflammation in rheumatoid arthritis.
    Firestein GS
    N Engl J Med; 2006 Jan; 354(1):80-2. PubMed ID: 16394307
    [No Abstract]   [Full Text] [Related]  

  • 13. The BeSt story: on strategy trials in rheumatoid arthritis.
    Klarenbeek NB; Allaart CF; Kerstens PJ; Huizinga TW; Dijkmans BA
    Curr Opin Rheumatol; 2009 May; 21(3):291-8. PubMed ID: 19318946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
    Gillooly KM; Pattoli MA; Taylor TL; Chen L; Cheng L; Gregor KR; Whitney GS; Susulic V; Watterson SH; Kempson J; Pitts WJ; Booth-Lute H; Yang G; Davies P; Kukral DW; Strnad J; McIntyre KW; Darienzo CJ; Salter-Cid L; Yang Z; Wang-Iverson DB; Burke JR
    J Pharmacol Exp Ther; 2009 Nov; 331(2):349-60. PubMed ID: 19652024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How can we improve adherence to therapy by patients with rheumatoid arthritis?
    van den Bemt BJ; van Lankveld WG
    Nat Clin Pract Rheumatol; 2007 Dec; 3(12):681. PubMed ID: 18037928
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug survival in rheumatoid arthritis.
    Mulherin D; Wong M
    Rheumatology (Oxford); 2006 Sep; 45(9):1178; author reply 1178-9. PubMed ID: 16861706
    [No Abstract]   [Full Text] [Related]  

  • 17. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?
    Bansard C; Lequerré T; Daveau M; Boyer O; Tron F; Salier JP; Vittecoq O; Le-Loët X
    Rheumatology (Oxford); 2009 Sep; 48(9):1021-8. PubMed ID: 19483089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to dose infliximab in rheumatoid arthritis: new data on a serious issue.
    van Vollenhoven RF
    Ann Rheum Dis; 2009 Aug; 68(8):1237-9. PubMed ID: 19605741
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide.
    Cronstein BN
    Arthritis Rheum; 2004 Jul; 50(7):2041-3. PubMed ID: 15248200
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of combination therapy in rheumatoid arthritis: comment on the review by Smolen et al.
    Möttönen T; Hannonen P; Leirisalo-Repo M; Korpela M; Hakala M; Kautiainen H;
    Arthritis Rheum; 2006 Jun; 54(6):2032-4; author reply 2034-5. PubMed ID: 16732573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.